PharmacoEconomics & Outcomes News 558 - 26 Jul 2008

Antihypertensive therapy incursvaried cost in Australia

Mean annual costs associated with antihypertensiveuse for atherothrombosis prevention vary according topatients’ risk factors, shows an analysis of such datacarried out by the Australian Reduction ofAtherothrombosis for Continued Health (REACH)registry.

Among 2783 patients at risk of atherothrombosis,antihypertensive therapy cost a mean of $A461* per year– the cost was "slightly higher" for female than malepatients ($A487 vs $A447; p < 0.001), which is"interesting and warrants further investigation", notethe researchers. The presence of coronary artery diseasealso added significantly to the costs, though this effectwas expected.* Australian dollars

Ademi Z, et al. Mean annual costs of antihypertensive therapy among patients atrisk of atherothrombosis - data from the Reduction of Atherothrombosis forContinued Health (REACH) registry. Journal of Hypertension 26 (Suppl. 1): 57abstr. PS02/MON/25, 2008 801119016

1

PharmacoEconomics & Outcomes News 26 Jul 2008 No. 5581173-5503/10/0558-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved